Pyrotinib also demonstrated promising effects in brain metastatic HER2-positive breast cancer regardless of whether patients were previously treated with trastuzumab (Ma et al., 2019; (Anwar et al., 2021). Here, ERBB2 is linked to breast carcinoma.